These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31222716)

  • 21. Promising new combination therapy for non-GCB DLBCL.
    Gourd E
    Lancet Oncol; 2019 May; 20(5):e245. PubMed ID: 30930026
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
    Kühnl A; Peckitt C; Patel B; Ardeshna KM; Macheta MP; Radford J; Johnson R; Paneesha S; Barton S; Chau I; Begum R; Valeri N; Wotherspoon A; Du Y; Zerizer I; Cunningham D
    Ann Hematol; 2020 Jan; 99(1):105-112. PubMed ID: 31776726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
    Hara T; Yoshikawa T; Goto H; Sawada M; Yamada T; Fukuno K; Kasahara S; Shibata Y; Matsumoto T; Mabuchi R; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Nannya Y; Katsumura N; Takahashi T; Kito Y; Takami T; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
    Hematol Oncol; 2018 Oct; 36(4):638-644. PubMed ID: 29882279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
    Nowakowski GS; Hong F; Scott DW; Macon WR; King RL; Habermann TM; Wagner-Johnston N; Casulo C; Wade JL; Nagargoje GG; Reynolds CM; Cohen JB; Khan N; Amengual JE; Richards KL; Little RF; Leonard JP; Friedberg JW; Kostakoglu L; Kahl BS; Witzig TE
    J Clin Oncol; 2021 Apr; 39(12):1329-1338. PubMed ID: 33555941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
    J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
    Jain MD; Lam R; Liu Z; Stubbins RJ; Kahlon A; Kansara R; Goswami R; Humar A; Prica A; Sehn LH; Slack GW; Crump M; Savage KJ; Peters AC; Kuruvilla J
    Br J Haematol; 2020 Apr; 189(1):97-105. PubMed ID: 32068243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
    J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
    Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
    Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
    Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
    Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
    Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
    Nowakowski GS; Chiappella A; Gascoyne RD; Scott DW; Zhang Q; Jurczak W; Özcan M; Hong X; Zhu J; Jin J; Belada D; Bergua JM; Piazza F; Mócikova H; Molinari AL; Yoon DH; Cavallo F; Tani M; Yamamoto K; Izutsu K; Kato K; Czuczman M; Hersey S; Kilcoyne A; Russo J; Hudak K; Zhang J; Wade S; Witzig TE; Vitolo U
    J Clin Oncol; 2021 Apr; 39(12):1317-1328. PubMed ID: 33621109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
    Friedrichs B; Nickelsen M; Ziepert M; Altmann B; Haenel M; Viardot A; Schmidt C; Ruebe C; Loeffler M; Pfreundschuh M; Rosenwald A; Glass B; Lenz G; Schmitz N;
    Br J Haematol; 2019 Mar; 184(5):760-768. PubMed ID: 30520013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
    Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
    Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
    Straus DJ; Hamlin PA; Matasar MJ; Lia Palomba M; Drullinsky PR; Zelenetz AD; Gerecitano JF; Noy A; Hamilton AM; Elstrom R; Wegner B; Wortman K; Cella D
    Br J Haematol; 2015 Mar; 168(5):663-70. PubMed ID: 25316653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome.
    Mörth C; Valachis A; Abu Sabaa A; Marshall K; Hedström G; Flogegård M; Baecklund E; Enblad G
    Acta Oncol; 2019 Aug; 58(8):1170-1177. PubMed ID: 31131659
    [No Abstract]   [Full Text] [Related]  

  • 38. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
    Kadota T; Seo S; Fuse H; Ishii G; Itoh K; Yano T; Kaneko K; Tsukasaki K
    Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
    Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields PA; Gunawan A; Oliver R; Booth S; McMillan A; Fox CP; Bishton M; Collins GP; Hatton CSR
    Br J Haematol; 2019 Aug; 186(4):e94-e98. PubMed ID: 31020646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.